RT Journal Article
SR Electronic
T1 Using sero-epidemiology to monitor disparities in vaccination and infection with SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.06.21264573
DO 10.1101/2021.10.06.21264573
A1 Isobel Routledge
A1 Saki Takahashi
A1 Adrienne Epstein
A1 Jill Hakim
A1 Owen Janson
A1 Keirstinne Turcios
A1 Jo Vinden
A1 John Tomas Risos
A1 Margaret Rose Baniqued
A1 Lori Pham
A1 Clara Di Germanio
A1 Michael Busch
A1 Margot Kushel
A1 Bryan Greenhouse
A1 Isabel Rodríguez-Barraquer
YR 2021
UL http://medrxiv.org/content/early/2021/10/20/2021.10.06.21264573.abstract
AB Background As COVID-19 vaccines continue to be rolled-out, the “double burden” of health disparities in both exposure to infection and vaccination coverage intersect to determine the current and future patterns of infection, immunity, and mortality. Serology provides a unique opportunity to measure biomarkers of infection and vaccination simultaneously, and to relate these metrics to demographic and geographic factors.Methods Leveraging algorithmically selected residual serum samples from two hospital networks in San Francisco, we sampled 1014 individuals during February 2021, capturing transmission during the first 11 months of the epidemic and the early roll out of vaccination. These samples were tested using two serologic assays: one detecting antibodies elicited by infection, and not by vaccines, and one detecting antibodies elicited by both infection and vaccination. We used Bayesian statistical models to estimate the proportion of the population that was naturally infected and the proportion protected due to vaccination.Findings We estimated that the risk of prior infection of Latinx residents was 5.3 (95% CI: 3.2 - 10.3) times greater than the risk of white residents aged 18-64 and that white San Francisco residents over the age of 65 were twice as likely (2.0, 95% CI: 1.1 - 4.6) to be vaccinated as Black residents. We also found socioeconomically deprived zipcodes in the city had high probabilities of natural infections and lower vaccination coverage than wealthier zipcodes.Interpretation Using a platform we created for SARS-CoV-2 serologic data collection in San Francisco, we characterized and quantified the stark disparities in infection rates and vaccine coverage by demographic groups over the first year of the pandemic. While the arrival of the SARS-CoV-2 vaccine has created a ‘light at the end of the tunnel’ for this pandemic, ongoing challenges in achieving and maintaining equity must also be considered.Funding NIH, NIGMS, Schmidt Science Fellows in partnership with the Rhodes Trust and the Chan Zuckerberg Biohub.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge sources of funding support, including from the Schmidt Science Fellows, in partnership with the Rhodes Trust (ST); Chan Zuckerberg Biohub Investigator program (BG); the ZSFG Department of Medicine and Division of HIV, ID, and Global Medicine; the MIDAS Coordination Center COVID-19 Urgent Grant Program (MIDASNI2020-5) by a grant from the National Institute of General Medical Science (3U24GM132013-02S2) (IR, ST, IRB); and the National Institutes of Health/National Institute of General Medical Sciences R35GM138361-02 (IRB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received expedited review approval by the UCSF IRB #20-30379 (Serological Surveillance of SARS-CoV-2 in Residual Serum/Plasma Samples).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code to generate results will be available at https://github.com/EPPIcenter/scale-it-2